TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Maria E Cabanillas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.